Charles River Laboratories (CRL) Tops Q3 EPS by 9c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts CRL Hot Sheet
Price: $282.18 -2.19%
EPS Growth %: +21.8%
Financial Fact:
Net sales related to products: 132.87M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +21.8%
Financial Fact:
Net sales related to products: 132.87M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q3 EPS of $2.43, $0.09 better than the analyst estimate of $2.34. Revenue for the quarter came in at $1 billion versus the consensus estimate of $987.43 million.
GUIDANCE:
Charles River Laboratories sees FY2025 EPS of $10.10-$10.30, versus the consensus of $10.19.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bessent: We Make A Market Buying Older Bonds
- Hyperion DeFi, Inc. (HYPD) PT Raised to $8.45 at Chardan
- HSBC Raises S&P500 Target to 8,100
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
